Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CLOTHING”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,729 records · Page 96Linked to original sources
PubMed2006

Wolf in wolf's clothing--a case of prosthetic aortic valve thrombosis presenting as an acute coronary syndrome.

Mechanical prosthetic valve thrombosis (PVT) is a potentially life threatening event that occurs with an incidence of 0.2% per patient year following aortic valve replacement [Lengyel M, Fuster V, Keltal M, et al. Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. J Am Coll Cardiol 1997;30:1521-6]. We present the case of a middle-aged man with thrombosis of his aortic valve prosthesis mimicking an acute coronary syndrome. The patient received thrombolytic therapy with subsequent embolism of thrombotic debris to the leg.

Acute Disease↗
PubMed2003

HLA-G in skin cancer: a wolf in sheep's clothing?

Despite well-defined and immunogenic tumor antigens, and even in the presence of tumor antigen-specific cytotoxic cells, the immune system does not appear to be very effective in eradicating cells that have undergone malignant transformation. Tumor cells, even though invading and representing a threat, are not truly "foreign" but autologous cells that have become transformed in a subtle way, enabling them to escape the host immune system. Melanoma, and to less extent nonmelanoma, skin cancers have developed different strategies to circumvent host immunosurveillance. HLA-G is one of the molecules implicated in cancer immunescape. This review will concentrate on induction and expression of this nonclassical class I molecule in different skin cancer types presenting existing experimental evidence on this topic.

Cytotoxicity, Immunologic↗
PubMed2006

EU biotech crop regulations and environmental risk: a case of the emperor's new clothes?

European Union Commissioner for the Environment Stavros Dimas recently hailed 'upgraded' non-genetically modified (GM) crops as an alternative to GM crops. A comparative analysis of the environmental risks associated with such non-GM herbicide-resistant crops and GM herbicide-resistant crops is presented here. The analysis highlights serious weaknesses in the European Union (EU) regulatory framework, and the contradictory policy of the EU Commission on the precautionary principle is also shown. The continued political stance of ignoring these regulatory and policy inconsistencies is examined and found to be flawed. It is postulated that, even in the face of these flaws and coupled with recent statements from the UK drawing attention to inconsistencies in the EU regulatory framework, the EU will continue to ignore the real and present environmental risks associated with upgraded non-GM crops for biopolitical reasons.

Agriculture↗
PubMed1975

Late stenosis of Starr-Edwards cloth-covered prostheses.

During a two-year period (August, 1971, to July, 1973) 1 Starr-Edwards Model 2400 and 135 Starr-Edwards Model 2320 aortic prostheses were inserted without postoperative antiocagulant therapy. Seven of these valves (including the Model 2400 prosthesis) have been replaced because of substantial transvalvular gradients resulting from fibrous overgrowth of the valve orifice. Symptoms associated with aortic stenosis occurred an average of nine months after the initial operation. Six patients had severe anemia (packed cell volume less than 30%) and hemolysis (serum lactic dehydrogenase greater than 900 units). Gradients across the prostheses ranged from 66 to 105 mm Hg with a mean of 87 mm Hg. One valve was size 8A, 3 were 10A, and 1 was 12A. Fibrous ingrowth was not observed in an earlier group of 23 patients receiving the Model 2310 or Model 2320 prosthesis who were placed on long-term anticoagulant therapy. These findings, coupled with a 9% incidence of thromboembolism at one year, indicate that patients having these prostheses inserted should receive long-term anticoagulant therapy.

Adult↗